A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine : A Randomized, Observer-Blinded, Active-Controlled Study to Evaluate the Safety and Immunogenicity of a SARS CoV 2 rS Nanoparticle and Trivalent Hemagglutinin Nanoparticle Influenza Combination Vaccine With Matrix-M™ Adjuvant in Participants ≥ 50 Years of Age
This is a randomized, observer-blinded, active-controlled Phase 3 study to demonstrate the noninferior immunogenicity of a coronavirus disease 2019 (COVID-19) and influenza combination (CIC) vaccine relative to age-appropriate licensed influenza vaccine comparators in terms of hemagglutinin inhibition (HAI) response and Novavax COVID-19 Vaccine in terms of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibody (NAb) response and to further evaluate the safety and immunogenicity of a CIC vaccine..
| Medienart: |
|
|---|
Klinische Studie| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
ClinicalTrials.gov - (2024) vom: 20. März Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
610 |
|---|
| Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: March 4, 2024, Last downloaded: ClinicalTrials.gov processed this data on March 27, 2024, Last updated: March 27, 2024 |
|---|
| Study ID: |
NCT06291857 |
|---|---|
| Veröffentlichungen zur Studie: |
|
| fisyears: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
CTG000074969 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CTG000074969 | ||
| 003 | DE-627 | ||
| 005 | 20240327010431.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240313s2024 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)CTG000074969 | ||
| 035 | |a (UBBS_Klinische_Studien)NCT06291857 | ||
| 035 | |a (UBBS_Klinische_Studien)CIC-E-301 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine |b A Randomized, Observer-Blinded, Active-Controlled Study to Evaluate the Safety and Immunogenicity of a SARS CoV 2 rS Nanoparticle and Trivalent Hemagglutinin Nanoparticle Influenza Combination Vaccine With Matrix-M™ Adjuvant in Participants ≥ 50 Years of Age |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: March 4, 2024, Last downloaded: ClinicalTrials.gov processed this data on March 27, 2024, Last updated: March 27, 2024 | ||
| 520 | |a This is a randomized, observer-blinded, active-controlled Phase 3 study to demonstrate the noninferior immunogenicity of a coronavirus disease 2019 (COVID-19) and influenza combination (CIC) vaccine relative to age-appropriate licensed influenza vaccine comparators in terms of hemagglutinin inhibition (HAI) response and Novavax COVID-19 Vaccine in terms of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibody (NAb) response and to further evaluate the safety and immunogenicity of a CIC vaccine. | ||
| 650 | 2 | |a COVID-19 | |
| 650 | 2 | |a Influenza, Human | |
| 650 | 4 | |a Study Type: Interventional | |
| 650 | 4 | |a Recruitment Status: Not yet recruiting | |
| 650 | 4 | |a Phase: Phase 2, Phase 3 | |
| 650 | 4 | |a 610 | |
| 773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2024) vom: 20. März |
| 773 | 1 | 8 | |g year:2024 |g day:20 |g month:03 |
| 856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT06291857 |z kostenfrei |3 Volltext |
| 912 | |a GBV_CTG | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 20 |c 03 | ||